This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Potential Therapeutic Role of Antileukotriene Agents

Lewis J. Smith, MD

Arch Intern Med. 1996;156(19):2181-2189.

Abstract
Recent advances in research have led to the identification of an inflammatory component to asthma. Although many endogenous mediators are involved in inflammation, leukotrienes appear to play an especially important role in asthma. The leukotrienes produce tissue edema, mucus secretion, and smooth-muscle proliferation, along with a powerful bronchoconstriction. In addition, antileukotriene drugs have emerged as potential therapeutic agents for asthma. This study was designed to review the current information on these new agents. In this review, full-length articles of antileukotriene agents are examined. These articles were found through MEDLINE under the following medical headings: asthma, inflammation, leukotriene, leukotriene-receptor antagonist, and leukotriene-synthesis inhibitor. Most clinical studies cited are placebo-controlled trials involving healthy individuals and patients with asthma. These studies indicate that antileukotriene agents improve lung function and reduce the symptoms of asthma and the need for additional medication. Drugs that inhibit leukotriene-receptor binding and leukotriene synthesis hold promise as new additions to the armamentarium of clinicians who treat asthma. Furthermore, these drugs have already helped to elucidate some details of the pathophysiological features of asthma. Arch Intern Med. 1996;156:2181-2189

Author Affiliations
From the Pulmonary Division, Northwestern University Medical School, Chicago, Ill.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Comparison Study between the Mechanisms of Allergic Asthma Amelioration by a Cysteinyl-Leukotriene Type 1 Receptor Antagonist Montelukast and Methylprednisolone
Murai et al.
J. Pharmacol. Exp. Ther. 2005;312:432-440.
ABSTRACT | FULL TEXT  

Treatment of Allergic Asthma by Targeting Janus Kinase 3-Dependent Leukotriene Synthesis in Mast Cells with 4-(3',5'-Dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97)
Malaviya et al.
J. Pharmacol. Exp. Ther. 2000;295:912-926.
ABSTRACT | FULL TEXT  

Priming of Alveolar Macrophages by Leukotriene D4 . Potentiation of Inflammation
Ménard and Bissonnette
Am. J. Respir. Cell Mol. Bio. 2000;23:572-577.
ABSTRACT | FULL TEXT  

Current Outpatient Management of Asthma Shows Poor Compliance With International Consensus Guidelines*
Taylor et al.
Chest 1999;116:1638-1645.
ABSTRACT | FULL TEXT  

Inflammatory Mediators of Asthma: An Update
Barnes et al.
Pharmacol. Rev. 1998;50:515-596.
ABSTRACT | FULL TEXT  

Continuous release of vasodilator prostanoids contributes to regulation of resting forearm blood flow in humans
Duffy et al.
Am. J. Physiol. Heart Circ. Physiol. 1998;274:H1174-H1183.
ABSTRACT | FULL TEXT  

The Pathophysiology of Asthma
Vondracek and Stanaszek
Journal of Pharmacy Practice 1997;10:176-185.
ABSTRACT